SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001214659-24-005088
Filing Date
2024-03-25
Accepted
2024-03-25 17:27:31
Documents
56
Period of Report
2024-01-31

Document Format Files

Seq Description Document Type Size
1 az3424010q.htm   iXBRL 10-Q 842540
2 EXHIBIT 31.1 ex31_1.htm EX-31.1 7855
3 EXHIBIT 31.2 ex31_2.htm EX-31.2 7767
4 EXHIBIT 32.1 ex32_1.htm EX-32.1 4930
  Complete submission text file 0001214659-24-005088.txt   4026658

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE alzm-20240131.xsd EX-101.SCH 39124
6 XBRL CALCULATION FILE alzm-20240131_cal.xml EX-101.CAL 32840
7 XBRL DEFINITION FILE alzm-20240131_def.xml EX-101.DEF 137769
8 XBRL LABEL FILE alzm-20240131_lab.xml EX-101.LAB 274297
9 XBRL PRESENTATION FILE alzm-20240131_pre.xml EX-101.PRE 219921
59 EXTRACTED XBRL INSTANCE DOCUMENT az3424010q_htm.xml XML 533885
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 10-Q | Act: 34 | File No.: 001-40483 | Film No.: 24780252
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)